辅助内分泌治疗对Ⅰ期子宫内膜癌的临床有效性分析  

Analysis of the Clinical Effectiveness of Adjuvant Endocrine Therapy for StageⅠEndometrial Cancer

作　　者：林亮[1] 陈瓅[1] 李玲[1] 陈建[1] 谢佐莲 林安[1] LIN Liang;CHEN Li;LI Ling;CHEN Jian;XIE Zuolian;LIN An(Department of Oncology,Fujian Cancer Hospital,Fuzhou,Fujian Province,350014 China)

机构地区：[1]福建省肿瘤医院肿瘤科,福建福州350014

出　　处：《中外医疗》2021年第36期58-60,68,共4页China & Foreign Medical Treatment

摘　　要：目的探讨对Ⅰ期子宫内膜癌患者实施辅助内分泌治疗后获得临床效果。方法随机选取福建省肿瘤医院2015年1月—2020年12月收治的100例Ⅰ期子宫内膜癌患者进行治疗研究,随机分为参照组(在手术治疗基础上,未对患者实施辅助内分泌治疗)和研究组(在手术治疗及需要放疗基础上,对患者实施辅助内分泌治疗),各50例。比较两组患者治疗总有效率、无瘤存活率、复发转移率、因癌病死率。结果同参照组治疗总有效率(78.00%)比较,研究组(96.00%)呈现出显著提高,差异有统计学意义(χ^(2)=7.161,P<0.05);研究组无瘤存活率(96.00%)、复发转移率(2.00%)同参照组无瘤存活率(92.00%)、复发转移率(2.00%)比较,差异无统计学意义(χ^(2)=0.177、0.000,P>0.05);研究组因癌病死率(2.00%)低于参照组(6.00%),差异无统计学意义(P>0.05)。结论临床针对Ⅰ期子宫内膜癌患者合理展开辅助内分泌治疗,可有效增强疾病治疗效果,将其因癌病死率显著降低,获得效果确切,可促进Ⅰ期子宫内膜癌患者预后水平显著提升。Objective To explore the clinical effect of adjuvant endocrine therapy for patients with stage I endometrial cancer.Methods A total of 100 patients with stage I endometrial cancer admitted to Fujian Cancer Hospital from January 2015 to December 2020 were randomly selected for treatment research.They were randomly divided into a reference group(on the basis of surgical treatment,no adjuvant endocrine therapy was given to patients)and a research group(on the basis of surgery and radiotherapy,adjuvant endocrine therapy was given to patients),each with 50 cases.The total effective rate of treatment,tumor-free survival rate,recurrence and metastasis rate,and cancer mortality were compared between the two groups.Results Compared with the total effective rate of treatment in the reference group(78.00%),the study group(96.00%),and the difference was statistically significant(χ^(2)=7.161,P<0.05).Compared with the tumor-free survival rate(92.00%)and recurrence and metastasis rate(2.00%)of the reference group,the tumor-free survival rate(96.00%)and recurrence and metastasis rate(2.00%)of the study group,and the difference was not statistically significant(χ^(2)=0.177,0.000,P>0.05).The cancer mortality rate(2.00%)in the study group was lower than that in the reference group(6.00%),and the difference was not statistically significant(P>0.05).Results The clinical application of adjuvant endocrine therapy for patients with stage I endometrial cancer can effectively enhance the treatment effect of the disease,significantly reduce the death rate due to cancer,and obtain definite results.It can significantly improve the prognosis of patients with stage I endometrial cancer.

关 键 词：Ⅰ期子宫内膜癌患者 辅助内分泌治疗 治疗总有效率 无瘤存活率 复发转移率 因癌病死率 

分 类 号：R737.33[医药卫生—肿瘤]